Participants completed validated measures of food allergy-related QoL and perceived risk of negative food allergy outcomes at baseline and study conclusion (week 52), and an interview about peanut ...consumption at week 52.
Eczema Area and Severity Index (EASI), Rajka-Langeland severity score, past staphylococcal infection, past eczema herpeticum (EH) and laboratory test results were compared amongst the age of AD onset ...groups.
Methods We use whole genome sequencing on 493 European American AD subjects (average age = 26, average severity measured by EASI score = 14.5) and 237 non-atopic controls in the Atopic Dermatitis ...Research Network (ADRN) study to test for association with single nucleotide polymorphisms (SNPs) in the EDC as risk determinants of AD as well as severity of disease.
Rationale Peanut oral immunotherapy (OIT) is a promising approach to peanut allergy but reactions frequently occur and some patients cannot be desensitized.
Contribution of FLG mutations to S. aureus colonization in mild, moderate and severe AD was assessed by including interaction between EASI and FLG mutations in logistic regression models adjusting ...for total IgE, age, and sex.
Methods In a multicenter double-blind, placebo-controlled phase IIb trial, 221 subjects (6 - 55 years) reacting at a peanut protein (pp) eliciting-dose (ED) <=300mg during DBPCFC were randomized to 1 ...year Viaskin® Peanut (VP), at different doses (50microg, 100microg, 250microg pp), or Viaskin®placebo.
Rationale Null mutations in Filaggrin (FLG) located within the Epidermal Differentiation Complex (EDC; chr1:151972910-153642037) are known to increase risk for atopic dermatitis (AD); but the role of ...variants within additional genes in the EDC is not well understood.
While our evidence for risk of bacterial colonization is less striking in the EDC, extensive analysis is underway to include SNVs across the genome, insertion/deletions and gene-level tests.
PDF
